Tags : High Risk of Fracture


Amgen and UCB’s Evenity (Romosozumab) Receive CHMP Positive Opinion to

Shots: The EMA’s CHMP has adopted a positive opinion recommending marketing authorization for Evenity (romosozumab) based on P-III global studies including FRAME, ARCH and BRIDGE studies assessing Evenity vs PBO and active comparator in ~11,000 postmenopausal women with osteoporosis at high risk of fracture and with no history of MI or stroke The CHMP’s recommendation […]Read More